Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The current ruling will assure the safety of the use of Ranitidine for Indian patients
This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Subscribe To Our Newsletter & Stay Updated
